Literature DB >> 33769129

How to Help Your Patients Enroll in the New-Onset Refractory Status Epilepticus (NORSE) and Febrile Infection-Related Epilepsy Syndrome (FIRES) Family Registry, and Other Rare Epilepsy Registries.

Karnig Kazazian1, Marissa Kellogg2, Nora Wong3, Krista Eschbach4, Raquel Farias Moeller5, Nicolas Gaspard6, Lawrence J Hirsch7, Sara Hocker8, Teneille Gofton1.   

Abstract

Entities:  

Year:  2021        PMID: 33769129      PMCID: PMC8655258          DOI: 10.1177/15357597211002869

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN: 1535-7511            Impact factor:   7.500


× No keyword cloud information.
New-onset refractory status epilepticus (NORSE) is a rare clinical presentation of refractory status epilepticus (RSE) that occurs in people without active epilepsy or preexisting neurologic disorder. New-onset refractory status epilepticus does not resolve after 2 or more rescue antiseizure medications, and it presents without a clear acute or active structural, toxic, or metabolic etiology. Febrile infection-related epilepsy syndrome (FIRES) is a subcategory of NORSE and requires a febrile infection between 2 weeks and 24 hours before the start of RSE, with or without fever at the onset of RSE. New-onset refractory status epilepticus/FIRES are becoming increasingly recognized; however, information pertaining to disease course, clinical outcomes, and survivorship remains limited, and mortality and morbidity are variable but often high. The objective of the NORSE/FIRES Family Registry is to (1) provide an easily accessible and internationally available multilingual registry into which survivors or NORSE/FIRES surrogates or family members of people affected by NORSE/FIRES or their physicians can enter data in a systematic and rigorous research study from anywhere in the world where internet is available; and (2) to examine past medical history, outcomes, and quality of life for people affected by NORSE/FIRES. The NORSE Family registry invites survivors, their loved ones or substitute decision-makers to enter data along with their health care professionals. It is managed using REDCap (Research Electronic Data Capture tool) hosted at Lawson Health Research Institute, affiliated with Western University (London, ON, Canada). All participants must provide electronic informed consent before accessing the online survey. Within the survey we will ask questions about past medical history, clinical presentation, disease course, survivorship, clinical sequelae, and quality of life, among others. If applicable, the survey invites participants to return at 6, 12, and 24 months after disease onset to gather ongoing information on survivorship, long-term outcomes, and quality of life. If participants are already beyond 24 months after disease onset, they are invited to provide data regarding the same variables at the time they are completing the survey. The survey has several features to make data input accessible and user friendly, such as save and return options, email notifications, and detailed instructions for participants. The registry will remain open until 2025. The survey can be accessed at http://www.norseinstitute.org/norse-registry-2. The NORSE/FIRES Family Registry is a collaborative project developed by members of the NORSE Institute (www.norseinstitute.org). It will allow for the collection of a wide range of clinical and epidemiological variables which will provide a stepping stone for future systematic research. Most importantly, the NORSE/FIRES Family Registry provides an opportunity for families and survivors themselves to contribute directly to NORSE/FIRES research. The authors would like to acknowledge the Kohn Family, the generous support from the Robert N. Kohn Research Memorial Fund and all of the families and survivors of NORSE/FIRES who have been paramount in the development of this registry.

Editor’s Note

The table below provides a listing of registries derived from a recent Rare Epilepsy Landscape analysis. More details can be found in the original citation. Abbreviation: NORSE, new-onset refractory status epilepticus.
OrganizationOrganization or registry link
Batten Disease Support and Research Association https://www.bdsra.org/
Beta-propeller Protein-Associated Neurodegeneration (BPAN) https://www.nbiadisorders.org/research/patient-registry
Bridge the Gap—SYNGAP Education and Research Foundation https://www.bridgesyngap.org/
Cardiofaciocutaneous syndrome https://connect.invitae.com/org/cfc
CFC International https://www.cfcsyndrome.org/
Chelsea’s Hope https://chelseashope.org/
Christianson syndrome https://www.brown.edu/hassenfeld/content/international-christianson-syndrome-network
Chromosome 9pMinus Network https://www.9pminus.org/
DDX3X Foundation https://ddx3x.org/patient-registry/
DNM1 dynamos - Connecting DNM1 Families https://dnm1families.com/
Dravet Syndrome Foundation https://www.dravetfoundation.org/
Dup15q Alliance https://dup15q.org/
FamilieSCN2A Foundation https://www.scn2a.org/
Global Pediatric Epilepsy Surgery Registry https://www.brainrecoveryproject.org/research/patient-registry/
Glut1 Deficiency https://www.g1dregistry.org/
GNAO1 https://connect.invitae.com/org/gnao1
Hope for hypothalamic hamartomas https://www.hopeforhh.org/
International Foundation for CDKL5 Research https://www.cdkl5.com/cdkl5-international-registry-database/
KCNMA1 Channelopathy https://www.kciaf.org/registry
KCNMA1 Channelopathy International Advocacy Foundation (KCIAF) https://www.kciaf.org/
KIF1A https://www.kif1a.org/research/natural-history-study/
LGS Foundation https://www.lgsfoundation.org/
Linking Angelman and Dup15q Data for Expanded Research (LADDER) https://laddertotreatment.org/
Lissencephaly Foundation Inc https://www.lissfoundation.org/
NORSE Institute http://www.norseinstitute.org/norse-registry-2
North American AED Pregnancy Registry https://www.aedpregnancyregistry.org/
North American SUDEP Registry (NASR) http://sudepregistry.org/
Phelan-McDermid Syndrome Foundation https://www.pmsf.org/registry/
Project 8p https://project8p.org/
PVNH Support & Awareness https://pvnhsupport.com/
Ring14 USA http://www.ring14.org/eng/120/clinical-database/
SLC13A5 Deficiency https://www.tessresearch.org/families/
SLC6A1 Connect https://www.simonssearchlight.org/research/what-we-study/slc6a1/
SUDEP Tissue Donation Program (STOP SUDEP) https://www.bcm.edu/healthcare/clinical-trials/h-32343
SYNGAP1 https://syngap1registry.iamrare.org/
TESS Research Foundation https://www.tessresearch.org/
The Bow Foundation https://gnao1.org/
The Brain Recovery Project: Childhood Epilepsy Surgery Foundation https://www.brainrecoveryproject.org/
The Cute Syndrome https://www.thecutesyndrome.com/
Tuberous Sclerosis Alliance—Natural History Database https://www.tsalliance.org/researchers/natural-history-database/
Wishes for Elliott: Advancing SCN8A Research https://scn8a.net/

Abbreviation: NORSE, new-onset refractory status epilepticus.

  3 in total

Review 1.  New onset refractory status epilepticus research: What is on the horizon?

Authors:  Teneille E Gofton; Nicolas Gaspard; Sara E Hocker; Tobias Loddenkemper; Lawrence J Hirsch
Journal:  Neurology       Date:  2019-03-20       Impact factor: 9.910

Review 2.  Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions.

Authors:  Lawrence J Hirsch; Nicolas Gaspard; Andreas van Baalen; Rima Nabbout; Sophie Demeret; Tobias Loddenkemper; Vincent Navarro; Nicola Specchio; Lieven Lagae; Andrea O Rossetti; Sara Hocker; Teneille E Gofton; Nicholas S Abend; Emily J Gilmore; Cecil Hahn; Houman Khosravani; Felix Rosenow; Eugen Trinka
Journal:  Epilepsia       Date:  2018-02-05       Impact factor: 5.864

3.  Raring for change: Confluence of scientific discovery and advocate alignment warrants vital new investments in The Epilepsies.

Authors:  Ilene Penn Miller
Journal:  Epilepsy Behav       Date:  2020-08-01       Impact factor: 2.937

  3 in total
  1 in total

Review 1.  Fever-Associated Seizures or Epilepsy: An Overview of Old and Recent Literature Acquisitions.

Authors:  Piero Pavone; Xena Giada Pappalardo; Enrico Parano; Raffaele Falsaperla; Simona Domenica Marino; John Kane Fink; Martino Ruggieri
Journal:  Front Pediatr       Date:  2022-04-21       Impact factor: 3.569

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.